Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.92
RTRX's Cash-to-Debt is ranked lower than
64% of the 733 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. RTRX: 0.92 )
Ranked among companies with meaningful Cash-to-Debt only.
RTRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.22  Med: 5000.46 Max: No Debt
Current: 0.92
Equity-to-Asset 0.59
RTRX's Equity-to-Asset is ranked lower than
55% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. RTRX: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
RTRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.96  Med: 0.16 Max: 0.59
Current: 0.59
-0.96
0.59
Interest Coverage N/A
RTRX's Interest Coverage is ranked higher than
70% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 88.12 vs. RTRX: N/A )
Ranked among companies with meaningful Interest Coverage only.
RTRX' s Interest Coverage Range Over the Past 10 Years
Min: 175.78  Med: 9999.5 Max: No Debt
Current: N/A
Piotroski F-Score: 2
Beneish M-Score: -1.83
WACC vs ROIC
15.81%
-14.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -42.90
RTRX's Operating Margin % is ranked lower than
84% of the 686 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.19 vs. RTRX: -42.90 )
Ranked among companies with meaningful Operating Margin % only.
RTRX' s Operating Margin % Range Over the Past 10 Years
Min: -42.9  Med: 197.3 Max: 2105.03
Current: -42.9
-42.9
2105.03
Net Margin % -35.69
RTRX's Net Margin % is ranked lower than
84% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. RTRX: -35.69 )
Ranked among companies with meaningful Net Margin % only.
RTRX' s Net Margin % Range Over the Past 10 Years
Min: -35.69  Med: 199.98 Max: 2059.37
Current: -35.69
-35.69
2059.37
ROE % -15.46
RTRX's ROE % is ranked lower than
79% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. RTRX: -15.46 )
Ranked among companies with meaningful ROE % only.
RTRX' s ROE % Range Over the Past 10 Years
Min: -15.76  Med: 36.75 Max: 89.25
Current: -15.46
-15.76
89.25
ROA % -9.17
RTRX's ROA % is ranked lower than
78% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. RTRX: -9.17 )
Ranked among companies with meaningful ROA % only.
RTRX' s ROA % Range Over the Past 10 Years
Min: -575  Med: -240.01 Max: 36.2
Current: -9.17
-575
36.2
3-Year EBITDA Growth Rate -23.50
RTRX's 3-Year EBITDA Growth Rate is ranked lower than
90% of the 577 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. RTRX: -23.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RTRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -23.5
Current: -23.5
GuruFocus has detected 2 Warning Signs with Retrophin Inc $RTRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RTRX's 10-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Equity & Asset
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

RTRX Guru Trades in Q1 2016

Jim Simons 76,600 sh (New)
Paul Tudor Jones 24,165 sh (-9.38%)
» More
Q2 2016

RTRX Guru Trades in Q2 2016

Steven Cohen 174,800 sh (New)
Paul Tudor Jones 37,967 sh (+57.12%)
Jim Simons Sold Out
» More
Q3 2016

RTRX Guru Trades in Q3 2016

Lee Ainslie 148,661 sh (New)
Paul Tudor Jones 66,213 sh (+74.40%)
Steven Cohen 150,800 sh (-13.73%)
» More
Q4 2016

RTRX Guru Trades in Q4 2016

John Paulson 55,000 sh (New)
Jim Simons 41,300 sh (New)
Steven Cohen 412,735 sh (+173.70%)
Lee Ainslie Sold Out
Paul Tudor Jones 51,666 sh (-21.97%)
» More
» Details

Insider Trades

Latest Guru Trades with RTRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325411    SIC: 2834
Compare:OTCPK:BAYRY » details
Traded in other countries:17R.Germany,
Retrophin Inc is a fully integrated biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases.

Retrophin Inc was incorporated as Desert Gateway, Inc. as an Oklahoma corporation on February 8, 2008. On February 14, 2013, the Company changed its name to Retrophin, Inc. The Company is a fully integrated biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It is developing Syntocinon Nasal Spray in the U.S. to assist initial postpartum milk ejection, which it refers to as aiding milk let-down, and for the treatment of Schizophrenia and Autism. It is also developing RE-034, a synthetic hormone analogue that is composed of the first 24 amino acids of the 39 amino acids contained in the naturally occurring adrenocorticotrophic hormone, or ACTH, for the treatment of Infantile Spasms, or IS, and Nephrotic Syndrome, or NS. It is developing sparsentan, formerly known as RE-021, a dual acting receptor antagonist of angiotensin and endothelin receptors, for the treatment of focal segmental glomerulosclerosis, or FSGS. The Company competes with Genentech, GlaxoSmithKline, Roche, Novartis, Pfizer, Boehringer Ingelheim, Sanofi, BioMarin, Sarepta, Vertex, and Jazz Pharmaceuticals. The Company is subject to federal, state and local laws governing the use, handling and disposal of these materials.

Ratios

vs
industry
vs
history
PB Ratio 2.18
RTRX's PB Ratio is ranked higher than
64% of the 898 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. RTRX: 2.18 )
Ranked among companies with meaningful PB Ratio only.
RTRX' s PB Ratio Range Over the Past 10 Years
Min: 1.43  Med: 2.42 Max: 8.33
Current: 2.18
1.43
8.33
PS Ratio 4.93
RTRX's PS Ratio is ranked lower than
68% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. RTRX: 4.93 )
Ranked among companies with meaningful PS Ratio only.
RTRX' s PS Ratio Range Over the Past 10 Years
Min: 1.87  Med: 20.74 Max: 76.25
Current: 4.93
1.87
76.25

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -27.20
RTRX's 3-Year Average Share Buyback Ratio is ranked lower than
86% of the 446 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.00 vs. RTRX: -27.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RTRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -592.1  Med: -524.4 Max: -27.2
Current: -27.2
-592.1
-27.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 5.39
RTRX's Price-to-Tangible-Book is ranked lower than
63% of the 830 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.52 vs. RTRX: 5.39 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RTRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.12  Med: 5.44 Max: 5.79
Current: 5.39
5.12
5.79
Price-to-Intrinsic-Value-Projected-FCF 7.00
RTRX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
75% of the 422 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. RTRX: 7.00 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RTRX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 6.45  Med: 6.97 Max: 7.53
Current: 7
6.45
7.53
Price-to-Median-PS-Value 0.24
RTRX's Price-to-Median-PS-Value is ranked higher than
98% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.18 vs. RTRX: 0.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RTRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.2 Max: 0.26
Current: 0.24
0.15
0.26
Earnings Yield (Greenblatt) % -8.50
RTRX's Earnings Yield (Greenblatt) % is ranked lower than
82% of the 1021 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.62 vs. RTRX: -8.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RTRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -8.79  Med: 16.85 Max: 22.6
Current: -8.5
-8.79
22.6

More Statistics

Revenue (TTM) (Mil) $134.2
EPS (TTM) $ -1.67
Beta1.88
Short Percentage of Float15.99%
52-Week Range $11.60 - 24.57
Shares Outstanding (Mil)38.09
» More Articles for RTRX

Headlines

Articles On GuruFocus.com
Biotech Stocks to Watch After Senate Drug Report Dec 27 2016 
Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
Largest Insider Buys of the Week Apr 07 2014 
Weekly CEO Buys Highlight: OPK, RTRX, TFM, CSBK, AHP Apr 07 2014 
Three CEOs Reporting Large Insider Buys Apr 04 2014 
Steven Cohen Tops GuruFocus' Real Time Picks of the Week Apr 04 2014 
Morning Coffee: See Which Insiders are Buying Apr 04 2014 
Weekly CEO Buys Highlight: CLMS, OPK, OVAS, RTRX, MDCA Mar 17 2014 
Weekly CEO Buys Highlight: KMI, CLMS, RTRX, OPK, KO Mar 03 2014 
Weekly CEO Buys Highlight: RSE, RHP, RTRX, CLMS Jan 21 2014 

More From Other Websites
RETROPHIN, INC. Files SEC form 8-K, Change in Directors or Principal Officers Mar 27 2017
John A. Orwin Joins Retrophin Board of Directors Mar 23 2017
Shire (SHPG) Rare Disease Drug Gets Fast Track Designation Mar 23 2017
Valeant's (VRX) Glaucoma Candidate Gets PDUFA Date from FDA Mar 21 2017
Mylan Receives Tentative Approval from FDA for HIV Therapy Mar 21 2017
Alnylam's LDL-Lowering Drug Positive in Phase II Study Mar 20 2017
Alexion (ALXN) Licenses Artubus Technology for Rare Diseases Mar 17 2017
Shire's (SHPG) Cinryze Label Expanded for Pediatric Use Mar 16 2017
Endo's (ENDP) Opana ER's Risk Benefit Evaluated by FDA Mar 16 2017
Martin Shkreli’s former biotech company Retrophin is leaving Cambridge Mar 09 2017
RETROPHIN, INC. Files SEC form 8-K, Costs Associated with Exit or Disposal Activities Mar 08 2017
RETROPHIN, INC. Financials Mar 08 2017
Retrophin to Present at the Barclays Global Healthcare Conference Mar 07 2017
Retrophin, Inc. :RTRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
Edited Transcript of RTRX earnings conference call or presentation 1-Mar-17 10:00pm GMT Mar 01 2017
Retrophin reports 4Q loss Mar 01 2017
Retrophin reports 4Q loss Mar 01 2017
RETROPHIN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 01 2017
Retrophin Provides Sparsentan Regulatory Update; Reports Fourth Quarter and Full Year 2016 Financial... Mar 01 2017
Q4 2016 Retrophin Inc Earnings Release - After Market Close Mar 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)